1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Kimberly-Clark

Anonymous board for Kimberly-Clark

Sort By:
Title
Replies Views
Last Message ↓
  1. Anonymous
    Replies:
    21
    Views:
    7,080
  2. Anonymous
    Replies:
    10
    Views:
    5,337
  3. Anonymous
    Replies:
    2
    Views:
    2,431
  4. Anonymous
    Replies:
    19
    Views:
    4,383
  5. Anonymous
    Replies:
    13
    Views:
    3,645
  6. Anonymous
    Replies:
    18
    Views:
    3,552
  7. Anonymous
    Replies:
    29
    Views:
    6,296
  8. Anonymous
    Replies:
    48
    Views:
    6,218
  9. Anonymous
    Replies:
    4
    Views:
    2,075
  10. Anonymous
    Replies:
    2
    Views:
    1,921
  11. Anonymous
    Replies:
    2
    Views:
    2,243
  12. Anonymous
    Replies:
    3
    Views:
    3,598
  13. Anonymous
    Replies:
    5
    Views:
    2,993
  14. Anonymous
    Replies:
    10
    Views:
    2,095
  15. Anonymous
    Replies:
    9
    Views:
    3,968
  16. Anonymous
    Replies:
    0
    Views:
    1,603
  17. Anonymous
    Replies:
    23
    Views:
    2,962
  18. Anonymous
    Replies:
    1
    Views:
    1,722
  19. Anonymous
    Replies:
    3
    Views:
    1,671
  20. Anonymous
    Replies:
    8
    Views:
    2,606

Thread Display Options

Loading...